Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Multi-Center, Prospective, Double Blind, Phase II Trial of RP- 1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Develop Malignant Edema

NCT01794182 is registered in ClinicalTrials.gov with Remedy Pharmaceuticals, Inc. as lead sponsor.

NCT NCT01794182
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01794182 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Multi-Center, Prospective, Double Blind, Phase II Trial of RP- 1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Develop Malignant Edema
Lead sponsor
Remedy Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Completed
Start date
June 13, 2013
Completion date
April 4, 2016
Enrollment
86 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

ischemic stroke, malignant edema